id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-318499-uihof6k6	Beddingfield, Brandon	The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection	2020-06-16		.txt	text/plain	1550	100	54	Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1integrin-based mechanism, and indicates that inhibiting α5β1 integrin interaction with ACE2 and the spike protein using a novel molecule ATN-161 represents a promising approach to treat COVID-19. In order to assess disruption of binding of α5β1 to SARS-CoV-2 Spike protein, 96-well plates were coated as before, but incubation with ATN-161 was performed in conjunction with 1µg/mL spike (produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, Wuhan-Hu-1, Recombinant from HEK293 Cells, NR-52306) in the presence of 1mM MnCl2, followed by detection with an anti-spike antibody. Inhibition of SARS-CoV-2 spike protein binding to human ACE2 by ATN-161.	./cache/cord-318499-uihof6k6.txt	./txt/cord-318499-uihof6k6.txt